Yvonne de Jong

546 citations

20 papers · 405 indexed · h-index 13

Co-authors: Judith V.M.G. Bovée Anne‐Marie Cleton-Jansen Erik H.J. Danen Alwine B. Kruisselbrink Hans Gelderblom Inge H. Briaire‐de Bruijn Elisabeth F.P. Peterse Bob van de Water
Topics: Sarcoma Diagnosis and Treatment (11 papers)Bone Tumor Diagnosis and Treatments (10 papers)Cancer-related molecular mechanisms research (4 papers)
Cited by: Rheumatology Cancer Research Pulmonary and Respiratory Medicine
Journals: SHILAP Revista de lepidopterologíaCancer Research Scientific Reports
Partner nations: Netherlands United States France

In The Last Decade

Yvonne de Jong

20 papers receiving 403 citations

Peers

Countries citing papers authored by Yvonne de Jong

Since Specialization

Citations

This map shows the geographic impact of Yvonne de Jong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yvonne de Jong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yvonne de Jong more than expected).

Fields of papers citing papers by Yvonne de Jong

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yvonne de Jong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yvonne de Jong. The network helps show where Yvonne de Jong may publish in the future.

Co-authorship network of co-authors of Yvonne de Jong

This figure shows the co-authorship network connecting the top 25 collaborators of Yvonne de Jong. A scholar is included among the top collaborators of Yvonne de Jong based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yvonne de Jong. Yvonne de Jong is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Correlation of gene expression with magnetic resonance imaging features of retinoblastoma: a multi-center radiogenomics validation study 2023 ·European Radiology ·(unknown),(unknown),Ogul E. Uner,Yvonne de Jong,(unknown),Sophia Göricke,Selma Sirin,Philippe Maeder,Paolo Galluzzi,Hervé J. Brisse,Liesbeth Cardoen,Jonas A. Castelijns,Paul van der Valk,Annette C. Moll,Hans E. Grossniklaus,G. Baker Hubbard,Marcus C. de Jong,Josephine C. Dorsman,Pim de Graaf	3
2	Genome-wide siRNA screens identify RBBP9 function as a potential target in Fanconi anaemia-deficient head-and-neck squamous cell carcinoma 2023 ·Communications Biology ·(unknown),(unknown),Davy Rockx,Yvonne de Jong,Chantal Stoepker,(unknown),Martin A. Rooimans,Lianne Vriend,Sander R. Piersma,Connie R. Jiménez,Renée X. de Menezes,Victor W. van Beusechem,Ruud H. Brakenhoff,Hein te Riele,Rob M.F. Wolthuis,Josephine C. Dorsman	1
3	BIRC2–BIRC3 amplification: a potentially druggable feature of a subset of head and neck cancers in patients with Fanconi anemia 2022 ·Scientific Reports ·(unknown),Yvonne de Jong,(unknown),(unknown),Klaas de Lint,Daoud Sie,Martin A. Rooimans,Davy Rockx,Elizabeth E. Hoskins,Najim Ameziane,Rob M.F. Wolthuis,Hans Joenje,Susanne I. Wells,Josephine C. Dorsman	7
4	High-Level MYCN-Amplified RB1-Proficient Retinoblastoma Tumors Retain Distinct Molecular Signatures 2022 ·SHILAP Revista de lepidopterología ·(unknown),Yvonne de Jong,Saskia E. van Mil,Armida W. M. Fabius,Annette C. Moll,Josephine C. Dorsman	12
5	Subretinal Fibrosis Detection Using Polarization Sensitive Optical Coherence Tomography 2020 ·Translational Vision Science & Technology ·(unknown),Jacoba A. van de Kreeke,(unknown),Boy Braaf,Yvonne de Jong,H. Stevie Tan,Frank D. Verbraak,Johannes F. de Boer	19
6	Exploration of the chondrosarcoma metabolome; the mTOR pathway as an important pro-survival pathway 2019 ·Journal of bone oncology ·Ruben D. Addie,Yvonne de Jong,(unknown),Alwine B. Kruisselbrink,Ivo Que,Hans J. Baelde,Judith V.M.G. Bovée	15
7	A screening-based approach identifies cell cycle regulators AURKA, CHK1 and PLK1 as targetable regulators of chondrosarcoma cell survival 2019 ·Journal of bone oncology ·Yvonne de Jong,(unknown),Jolieke G. van Oosterwijk,(unknown),(unknown),Pauline M. Wijers‐Koster,(unknown),Inge H. Briaire‐de Bruijn,(unknown),Hans J. Baelde,Anne‐Marie Cleton-Jansen,Bob van de Water,Erik H.J. Danen,Judith V.M.G. Bovée	6
8	Radiotherapy resistance in chondrosarcoma cells; a possible correlation with alterations in cell cycle related genes 2019 ·SHILAP Revista de lepidopterología ·Yvonne de Jong,(unknown),Inge H. Briaire‐de Bruijn,Alwine B. Kruisselbrink,(unknown),(unknown),Bram Heijs,Anne‐Marie Cleton-Jansen,(unknown),Judith V.M.G. Bovée	33
9	Inhibition of PARP Sensitizes Chondrosarcoma Cell Lines to Chemo- and Radiotherapy Irrespective of the IDH1 or IDH2 Mutation Status 2019 ·Cancers ·(unknown),Alwine B. Kruisselbrink,Inge H. Briaire‐de Bruijn,Yvonne de Jong,André J. van Wijnen,Erik H.J. Danen,Judith V.M.G. Bovée	22
10	Targeting glutaminolysis in chondrosarcoma in context of the IDH1/2 mutation 2018 ·British Journal of Cancer ·Elisabeth F.P. Peterse,(unknown),Ruben D. Addie,Yvonne de Jong,Arjen H.G. Cleven,Alwine B. Kruisselbrink,Brendy E.W.M. van den Akker,Remco J. Molenaar,Anne‐Marie Cleton-Jansen,Judith V.M.G. Bovée	38
11	Bcl-xl as the most promising Bcl-2 family member in targeted treatment of chondrosarcoma 2018 ·Oncogenesis ·Yvonne de Jong,(unknown),(unknown),(unknown),(unknown),Jolieke G. van Oosterwijk,Jean‐Yves Blay,Aurélie Dutour,Judith V.M.G. Bovée	41
12	High-Throughput Screening of Myxoid Liposarcoma Cell Lines: Survivin Is Essential for Tumor Growth 2017 ·Translational Oncology ·(unknown),Shruti Malu,(unknown),Alwine B. Kruisselbrink,Yvonne de Jong,Willem E. Corver,Hans Gelderblom,Patrick Hwu,Torsten O. Nielsen,Alexander J. Lazar,Neeta Somaiah,Judith V.M.G. Bovée	10
13	NAD Synthesis Pathway Interference Is a Viable Therapeutic Strategy for Chondrosarcoma 2017 ·Molecular Cancer Research ·Elisabeth F.P. Peterse,Brendy E.W.M. van den Akker,(unknown),Jan Oosting,Johnny Suijker,Yvonne de Jong,Erik H.J. Danen,Anne‐Marie Cleton-Jansen,Judith V.M.G. Bovée	37
14	Inhibition of Bcl-2 family members sensitizes mesenchymal chondrosarcoma to conventional chemotherapy: report on a novel mesenchymal chondrosarcoma cell line 2016 ·Laboratory Investigation ·Yvonne de Jong,(unknown),Adrián Mariño‐Enríquez,Daniëlle de Jong,Johnny Suijker,Inge H. Briaire‐de Bruijn,Alwine B. Kruisselbrink,Anne‐Marie Cleton-Jansen,Károly Szuhai,Hans Gelderblom,Jonathan A. Fletcher,Judith V.M.G. Bovée	27
15	Targeting survivin as a potential new treatment for chondrosarcoma of bone 2016 ·Oncogenesis ·Yvonne de Jong,Jolieke G. van Oosterwijk,Alwine B. Kruisselbrink,Inge H. Briaire‐de Bruijn,George Agrogiannis,(unknown),Arjen H.G. Cleven,(unknown),Bob van de Water,Erik H.J. Danen,Judith V.M.G. Bovée	29
16	No preclinical rationale for IGF1R directed therapy in chondrosarcoma of bone 2016 ·BMC Cancer ·Elisabeth F.P. Peterse,Arjen H.G. Cleven,Yvonne de Jong,Inge H. Briaire‐de Bruijn,Jonathan A. Fletcher,Erik H.J. Danen,Anne‐Marie Cleton-Jansen,Judith V.M.G. Bovée	4
17	Molecular oncogenesis of chondrosarcoma: impact for targeted treatment 2016 ·Current Opinion in Oncology ·Frank M. Speetjens,Yvonne de Jong,Hans Gelderblom,Judith V.M.G. Bovée	38
18	Abstract 3780: Aven-mediated checkpoint kinase control regulates proliferation and resistance to chemotherapy in osteosarcoma cells 2015 ·Cancer Research ·(unknown),(unknown),Yvonne de Jong,Jolieke G. van Oosterwijk,(unknown),Leo Price,Bob van de Water,Judith V.M.G. Bovée,Pancras C.W. Hogendoorn,Erik H.J. Danen	1
19	Pharmacological inhibition of Bcl-xL sensitizes osteosarcoma to doxorubicin 2015 ·Oncotarget ·(unknown),Yvonne de Jong,(unknown),Elisabeth F.P. Peterse,Anne‐Marie Cleton-Jansen,Bob van de Water,Pancras C.W. Hogendoorn,Judith V.M.G. Bovée,Erik H.J. Danen	36
20	MEK inhibition induces apoptosis in osteosarcoma cells with constitutive ERK1/2 phosphorylation 2015 ·Genes & Cancer ·(unknown),Tijmen H. Booij,Marieke L. Kuijjer,Yvonne de Jong,Anne‐Marie Cleton-Jansen,Leo Price,Bob van de Water,Judith V.M.G. Bovée,Pancras C.W. Hogendoorn,Erik H.J. Danen	26

About Yvonne de Jong

Yvonne de Jong is a scholar working on Rheumatology, Ophthalmology and Cancer Research, having authored 20 papers that have together received 405 indexed citations. Recurring topics across this work include Sarcoma Diagnosis and Treatment (11 papers), Bone Tumor Diagnosis and Treatments (10 papers) and Cancer-related molecular mechanisms research (4 papers). The work is most often cited by research in Rheumatology (139 citations), Cancer Research (134 citations) and Pulmonary and Respiratory Medicine (181 citations). Yvonne de Jong has collaborated with scholars based in Netherlands, United States and France. Frequent co-authors include Judith V.M.G. Bovée, Anne‐Marie Cleton-Jansen, Erik H.J. Danen, Alwine B. Kruisselbrink, Hans Gelderblom, Inge H. Briaire‐de Bruijn, Elisabeth F.P. Peterse, Bob van de Water, Frank M. Speetjens and Brendy E.W.M. van den Akker. Their work appears in journals such as SHILAP Revista de lepidopterología, Cancer Research and Scientific Reports.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact